Trevena Reports Third Quarter 2021 Results
November 15, 2021 07:00 ET
|
Trevena Inc.
-- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets Announced new OLINVYK cognitive function study vs. IV morphine, enrollment expected...
Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
November 11, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021
November 08, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients
September 30, 2021 07:00 ET
|
Trevena Inc.
-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality ~12 days lower average...
Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports Second Quarter 2021 Results
August 12, 2021 07:00 ET
|
Trevena Inc.
Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 NIH / Vanderbilt University Medical Center-led...
Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19
July 26, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial
May 06, 2021 07:03 ET
|
Trevena Inc.
-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS TRV027 to be dosed in ~300 COVID-19 patients -- CHESTERBROOK, Pa., May 06,...
Trevena Reports First Quarter 2021 Results
May 06, 2021 07:00 ET
|
Trevena Inc.
-- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and...
Trevena Announces TRV027 Selected for Study in Global REMAP-CAP Trial in COVID-19 Patients
April 21, 2021 07:00 ET
|
Trevena Inc.
-- REMAP-CAP is led by experts in pandemic response and builds upon a worldwide clinical trial network evaluating treatments for COVID-19 Interim review of Imperial College London TRV027 study data...